<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042805</url>
  </required_header>
  <id_info>
    <org_study_id>2019088</org_study_id>
    <nct_id>NCT04042805</nct_id>
  </id_info>
  <brief_title>Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma: A Single-arm, Open-label, Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baocai Xing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose
      of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined
      with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years after the last patient's enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of combination sintilimab and lenvatinib as evaluated by incidence of adverse events(AEs), serious adverse events (SAEs).</measure>
    <time_frame>2 years after the last patient's enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate to surgery</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>Conversion rate defined as the proportion of participants be able to receive surgery after the initiation of the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor mutation burden in association with ORR and survival.</measure>
    <time_frame>1 year after the last patient's enrollment</time_frame>
    <description>It will be performed by NGS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab Plus Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight &lt;60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg intravenously every 3 weeks</description>
    <arm_group_label>Sintilimab Plus Lenvatinib</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>12 mg (or 8 mg) once daily (QD) oral dosing.</description>
    <arm_group_label>Sintilimab Plus Lenvatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of hepatocellular carcinoma confirmed by radiology, histology, or
             cytology

          -  Barcelona Clinic Liver Cancer (BCLC) Stage C disease without any distant or lymphatic
             metastasis , or BCLC Stage B disease not amenable to curative surgery

          -  No previous systemic anticancer treatment or TACE treatment

          -  Age ≥18 years

          -  ECOG performance status: 0-1

          -  Child Pugh score≤7

          -  Has at least one measurable hepatocellular carcinoma (HCC) lesion based on RECIST 1.1

          -  Life expectancy ≥12 weeks.

          -  Patients must be able to understand and willing to sign a written informed consent
             document

        Exclusion Criteria:

          -  Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,
             cholangiocarcinoma

          -  History of hepatic encephalopathy or liver transplantation

          -  Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing
             drainage.

          -  Untreated hepatitis infection: HBV DNA&gt;2000IU/mlor10000 copy/ml, HCV RNA&gt; 1000copy/ml,
             both HbsAg and anti-HCV body are positive.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  History of symptomatic interstitial lung disease or other conditions that may cause
             confusion when discovering or managing suspicious drug-related lung toxicity

          -  With serious systemic diseases such as heart disease and cerebrovascular disease, and
             the condition is unstable or uncontrollable.

          -  Evidence of active pulmonary tuberculosis (TB).

          -  Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)

          -  History of allergic reactions to related drugs

          -  Pregnant women, nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baocai Xing, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baocai Xing, Doctor</last_name>
    <phone>+8613910721238</phone>
    <email>xingbaocai88@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lijun Wang, Doctor</last_name>
      <phone>+8615801154770</phone>
      <email>wanglijun1017@163.com</email>
    </contact>
    <investigator>
      <last_name>Baocai Xing, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Baocai Xing</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

